Damnacanthal Suppresses Breast Cancer Cells by Inducing Apoptosis and Cell Cycle Arrest via NF ‐ ĸB Signaling
Pharmacology Research & Perspectives · 2026-04 · 14 (2)
DOI: 10.1002/prp2.70249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 14.04.2026. Verfasst von Onnichar Jongcharoen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Anthraquinones, Breast Neoplasms, NF-kappa B, Antineoplastic Agents, Phytogenic. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science Achievement Scholarship of Thailand (SAST), The CIF, and CNI Grant, Faculty of Science, Mahidol University.
Abstract (Originalsprache)
Breast cancer is the most common cancer diagnosed and the leading cause of death for women worldwide. Noni ( Morinda citrifolia L.) contains an anthraquinone called damnacanthal (3‐hydroxy‐1‐methoxy‐anthraquinone‐2‐aldehyde), which is known to inhibit the growth of many types of cancer cells. The purpose of this study is to examine the anticancer effects of damnacanthal on cell proliferation, apoptosis, and cell cycle in breast cancer cells and its underlying signaling pathway, including nuclear factor kappa B (NF‐ĸB), epidermal growth factor receptors (EGFR), and PI3K/AKT/PTEN. Damnacanthal reduced cell viability in both normal and triple‐negative breast cancer cell lines, MCF‐7 and MDA‐MB‐231, respectively. In MCF‐7 cells, damnacanthal induced late apoptosis and increased cell cycle arrest in the G0/G1 and S phase, decreased RELA gene expression, and enhanced TNF‐α gene expression. However, it had no effect on the protein expression of PI3K/AKT. Damnacanthal exerted anticancer activity on MCF‐7 cell lines via blocking NF‐ĸB (subunit p65) expression at mRNA levels in the PI3K/AKT‐independent manner. These findings highlight the potential benefits of damnacanthal as a promising NF‐ĸB inhibitor for cancer prevention or treatment against breast carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand.
- Department of Pharmaceutical Botany, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
- Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Onnichar Jongcharoen, Warisara Parichatikanond
Förderung
- Science Achievement Scholarship of Thailand (SAST)
- The CIF, and CNI Grant, Faculty of Science, Mahidol University
Zitieren
APA
Jongcharoen, O., Reabroi, S., Sanvarinda, P., Tungmunnithum, D., Parichatikanond, W., & Pinthong, D. (2026). Damnacanthal Suppresses Breast Cancer Cells by Inducing Apoptosis and Cell Cycle Arrest via NF ‐ ĸB Signaling. Pharmacology Research & Perspectives, 14(2). https://doi.org/10.1002/prp2.70249
Vancouver
Jongcharoen O, Reabroi S, Sanvarinda P, Tungmunnithum D, Parichatikanond W, Pinthong D. Damnacanthal Suppresses Breast Cancer Cells by Inducing Apoptosis and Cell Cycle Arrest via NF ‐ ĸB Signaling. Pharmacology Research & Perspectives. 2026;14(2). doi:10.1002/prp2.70249
BibTeX
@article{Jongcharoen2026,
author = {Jongcharoen, Onnichar and Reabroi, Somrudee and Sanvarinda, Pimtip and Tungmunnithum, Duangjai and Parichatikanond, Warisara and Pinthong, Darawan},
title = {Damnacanthal Suppresses Breast Cancer Cells by Inducing Apoptosis and Cell Cycle Arrest via NF ‐ ĸB Signaling},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {2},
doi = {10.1002/prp2.70249}
}
EUVIMED